<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02288377</url>
  </required_header>
  <id_info>
    <org_study_id>PRODIGE31</org_study_id>
    <nct_id>NCT02288377</nct_id>
  </id_info>
  <brief_title>A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)</brief_title>
  <acronym>REMINET</acronym>
  <official_title>A EUROPEAN, MULTICENTRE, PHASE II/III RANDOMISED DOUBLE-BLIND, PLACEBO CONTROLLED STUDY EVALUATING LANREOTIDE AS MAINTENANCE THERAPY IN PATIENTS WITH NON-RESECTABLE DUODENO-PANCREATIC NEUROENDOCRINE TUMOURS AFTER FIRST-LINE TREATMENT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federation Francophone de Cancerologie Digestive</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federation Francophone de Cancerologie Digestive</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This European, prospective, multicentre, double-blind randomised study will evaluate the
      effect of lanreotide (120 mg every 28 days until disease progression) versus placebo in
      patients with metastatic/locally advanced, non-resectable, duodeno-pancreatic neuroendocrine
      tumours.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a European, prospective, multicentre, double-blind randomised study evaluating
      lanreotide (120 mg every 28 days until disease progression) versus placebo in patients with
      metastatic/locally advanced, non-resectable, duodeno-pancreatic neuroendocrine tumours.

      Depending on the phase II results, the study may be continued into phase III. The treatment
      and follow-up of patients will be the same in phase II and phase III.

      After the first-line treatment, patients will be randomly assigned with a 1:1 ratio to
      receive either lanreotide or placebo. The study treatment should be initiated within 6 weeks
      following the confirmation date of stable disease or objective response.

      Treatment period:

      For each patient, the investigational products (lanreotide or placebo) will be provided
      according to a double-blind procedure until disease progression or toxicity, in accordance
      with the protocol.

      The estimated average treatment duration for all patients is 12 months.

      Follow-up period:

      To evaluate overall survival, patients in phase II will have a minimum follow-up period of 12
      months; if the study continues to phase III, these patients will have a maximum follow-up
      period of 10 years. Phase III patients will have a minimum follow-up period of 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">January 2020</completion_date>
  <primary_completion_date type="Actual">January 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients alive and progression free at 6 months</measure>
    <time_frame>estimated 6 months after the last patient is randomized</time_frame>
    <description>To evaluate the rate of patients alive and progression free at 6 months, assessed by the investigator according to RECIST criteria (version 1.1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of patients alive and progression free at 12 months</measure>
    <time_frame>estimated 12 months after the last patient is randomized</time_frame>
    <description>To evaluate the rate of patients alive and progression free at 12 months, assessed by the investigator according to RECIST criteria (version 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The toxicities</measure>
    <time_frame>estimated 6 months after the last patient is randomized</time_frame>
    <description>Description using the NCI-CTC AE version 4.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours</condition>
  <arm_group>
    <arm_group_label>lanreotide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm, patients will receive lanreotide 120 mg every 28 days until disease progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In this arm, patients will receive placebo every 28 days until disease progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lanreotide</intervention_name>
    <description>Patients will receive lanreotide 120 mg every 28 days until disease progression</description>
    <arm_group_label>lanreotide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic (synchronous or metachronous) or locally advanced, non-resectable,
             well-differentiated duodeno-pancreatic neuroendocrine tumour, of grade 1 or 2 (WHO
             2010 classification; Ki-67 ≤ 20%)

          -  Progressive before first-line treatment

          -  Histologically confirmed (either on primary tumour or metastases)

          -  Pathological diagnosis validated by the NET consulting pathologist

          -  Documented stable disease or objective response after first-line treatment, within 4
             weeks (28 days) prior to randomisation

          -  The first-line treatment will consist of either a chemotherapy or biotherapy
             (everolimus or sunitinib) as referred to TNCD or ENETS guidelines. Treatment must have
             been administered for 3 to 6 months for chemotherapy and for 6 months for biotherapy

          -  Non-functional tumour or gastrinoma controlled by PPIs

          -  Age &gt; or = 18 years

          -  WHO 0, 1 or 2

          -  Effective contraception for male or female patients of childbearing age, defined as:
             oral contraceptives, intra-uterine devices, barrier contraceptive methods along with a
             spermicide gel, or surgical sterilisation. Female patients should use this
             contraception throughout the treatment period and for 6 months after the last
             treatment administration. Male patients should use contraception throughout the
             treatment period and for 3 months after the last treatment administration.

          -  Signed informed consent prior to initiation of any study-specific procedures or
             treatment.

        Exclusion Criteria:

          -  History of haematological malignancy or other cancer, except those treated for more
             than 5 years and considered as cured, carcinoma in situ of the cervix and treated skin
             cancer (excluding melanoma)

          -  Poorly differentiated neuroendocrine carcinoma or NET grade 3 ENETS (Ki-67 &gt; 20%)

          -  If primary resected, bone metastasis exclusively

          -  Pre-treatment by somatostatin long-acting analogue

          -  Total bilirubin ≥ 60 µmol/L

          -  Uncontrolled diabetes

          -  Contraindication to product used in the study or its components

          -  Tumour arising in the context of a genetic disease

          -  Pregnancy or lactation

          -  Patients unable to undergo medical follow-up due to geographical, social,
             psychological or legal reasons

          -  Concomitant participation in another clinical trial investigating a treatment during
             the treatment phase and within 30 days prior to the start of the study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Come Lepage, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federation Francophone de Cancerologie Digestive</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique Universitaire saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers - Hôtel Dieu</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU - Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Estaing</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Le Bocage Service d'HGE</name>
      <address>
        <city>Dijon Cedex</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Les Oudairies</name>
      <address>
        <city>La Roche Sur Yon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU La Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Source</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut Lévêque Bat Magellan, Service d'hépato-gastroentérologie</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Milétrie</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Saint Etienne</name>
      <address>
        <city>Saint Priest En Jarez</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Rangueil</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Campus Virchow Kilikum</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Marburg</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital Neuroendocrine Tumour Unit</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Academic Health Sciences Centre (MAHSC)</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Lepage C, Dahan L, Bouarioua N, Toumpanakis C, Legoux JL, Le Malicot K, Guimbaud R, Smith D, Tougeron D, Lievre A, Cadiot G, Di Fiore F, Bouhier-Leporrier K, Hentic O, Faroux R, Pavel M, Borbath I, Valle JW, Rinke A, Scoazec JY, Ducreux M, Walter T. Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours. Dig Liver Dis. 2017 May;49(5):568-571. doi: 10.1016/j.dld.2017.02.004. Epub 2017 Mar 11.</citation>
    <PMID>28292641</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 23, 2014</study_first_submitted>
  <study_first_submitted_qc>November 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2014</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lanreotide</keyword>
  <keyword>Duodeno-pancreatic neuroendocrine tumours</keyword>
  <keyword>Maintenance treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Adenoma, Islet Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lanreotide</mesh_term>
    <mesh_term>Angiopeptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

